Back to Research

Organization profile

Hylomorph

Hylomorph is a medtech company that develops bio-engineered, anti-fibrotic solutions to prevent postoperative complications in implantable medical devices. Its core technology, a bioresorbable surgical membrane, optimizes the interface between biological tissue and implants to reduce infection, fibrosis, and the need for revision surgeries.

Zurich, SwitzerlandFounded 2014

Overview

1. Executive Summary (Confidence: High)

Hylomorph AG, a 2014 ETH Zurich spin-off, has emerged as a disruptive leader in preventive surgical solutions for the implantable device market. The company’s flagship platform, Vesta, addresses the two most critical complications in cardiac implants: fibrotic encapsulation and systemic infection. After graduating from the Wyss Zurich accelerator in 2022, Hylomorph has successfully raised over $18 million in total funding, including an oversubscribed Series B2 round in 2023. With a recent CHF 2. million Innosuisse Swiss Accelerator grant, Hylomorph is currently transitioning to market launch in the US and EU, positioning its bioresorbable drug-eluting envelopes as the future gold standard for cardiac rhythm management (CRM) and neuromodulation.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.